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Abstract 
Background: German surveillance data showed a sharp rise of malaria cases in 2014 and 2015 due to the increased 
arrival of refugees from malaria endemic countries. A time series analysis of data from 2001 to 2016 was performed 
in order to describe the epidemiology of imported malaria in Germany in general and of the recent increase in 
particular.
Results: In total, 11,678 malaria cases were notified between 2001 and 2016 (range 526–1063 cases/year). Newly 
arriving refugees averaged 10 cases/year (1.5%) in 2001–13 and 292.5 cases/year (28.3%) in 2014–15. Plasmodium 
(P.) falciparum was the most frequently reported species (range 57.2–85.8%), followed by P. vivax (range during 
2001–2013: 7.6–18.1%; during 2014–2015, mean 31.3%). In 2014–15, 22.3% of all P. vivax cases were refugees from Eri‑
trea and 3.3% from other countries of the Horn of Africa; in 2015 and 2016, 19.5% were refugees from Afghanistan and 
Pakistan. Five P. knowlesi malaria infections were reportedly acquired in Thailand between 2012 and 2016. Total num‑
bers of malaria notifications among native Germans and residents with migration background showed an increasing 
trend since 2007. Chemoprophylaxis use was reported for 24.3% (1695/6984) of cases and showed a declining trend. 
Native German cases took significantly more frequently chemoprophylaxis than cases with migration background 
(32.6% vs. 17.9%; p < 0.001).
Discussion/conclusions: The steep rise in vivax malaria notifications in 2014 and 2015 was mainly due to newly 
arriving refugees from Eritrea but also from other countries of the Horn of Africa and South Asia. Clinicians should 
include malaria in their differential diagnosis in case of a febrile illness in the respective population and consider vivax 
malaria even if arrival to Germany dates back several months. Over the past 10 years, malaria notifications among native 
Germans and residents with migration background showed an increasing trend. Use of chemoprophylaxis was insufficient 
in both groups and deteriorating. New strategies need to be found to increase compliance to chemoprophylaxis recom‑
mendations. The surveillance provides valuable data for epidemiological assessment of imported malaria in Germany.
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Background
The number of malaria-endemic countries and territories 
has decreased since 2000 from 108 to 91 in 2016 [1]. The 
global malaria incidence rate was estimated to have fallen 
by 21% between 2010 and 2015. This success was largely 
attributed to widely deployed malaria control measures. 
The decline was most pronounced in Europe—Europe 
was declared malaria free in 2016 [2]—and South-East 
Asia and less marked in the African Region, where still 
90% of malaria infections occur [1].
In Germany, notified malaria infections are generally 
imported. Autochthonous vector borne transmissions are 
extremely rare events due to the timely treatment of par-
asitaemic patients, the lack of highly competent vectors, 
and the unfavourable climatic conditions [3, 4]. Trends 
in malaria epidemiology in Germany depend on the 
number of travellers to, and immigrants from malaria-
endemic countries, malaria endemicity at destination or 
home country, respectively, and the choices of the trav-
ellers regarding exposure prophylaxis and adherence 
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to chemoprophylaxis recommendations. Laboratory 
malaria diagnosis is notifiable to the national public 
health institute [Robert Koch-Institute (RKI)] accord-
ing to the German Infection Protection Act [5]. Malaria 
notification data are an important source for monitoring 
trends and provide information about the risk of travel-
lers to different destinations and about the impact of pre-
travel advice regarding chemoprophylaxis.
A sharp increase in malaria notifications occurred in 
2014, coinciding with a large influx of newly arriving refu-
gees in Germany. Roggelin et al. [6] reported an increase of 
vivax malaria in 2014–2015 in refugees from Eritrea admit-
ted to the University Medical Centre in Hamburg [6, 7], as 
also described in Sweden in 2014 [8, Sonden et al., personal 
communication], and the Netherlands in 2017 [9].
In order to obtain a better understanding of malaria 
epidemiology in Germany in general and of the recent 
increase in malaria cases in particular, time series analy-
sis using national notification data from the past 16 years 
was performed, aiming to describe demographic char-
acteristics of cases, distribution of Plasmodium species, 
countries of infection, and geographic origin of cases 
over the time period between 2001 and 2016. Chemopro-
phylaxis use and disease outcomes were also analysed.
Methods
Direct or indirect detection of any type of Plasmodium in 
human blood is notifiable by laboratories directly to RKI, 
in an anonymous manner, regardless of the applied labo-
ratory method. The RKI sends standardized data forms to 
laboratories for this purpose. Clinical data are added by 
an attending physician, filling in a second reporting form, 
which is forwarded to him or her by the laboratory. Both 
reporting forms are matched together at national level 
and entered into a database. The form asks for informa-
tion on month and year of birth, gender, the three first 
digits of the patient’s home post code, month and year of 
malaria diagnosis, Plasmodium species, geographic ori-
gin, if applicable date of immigration to Germany, travel 
history with dates, travel purpose and destinations, infor-
mation on prophylaxis and treatment, hospitalization 
and death. An automated algorithm identifies potential 
double entries. These are manually screened and datasets 
are excluded if they prove to belong to the same patient. 
Laboratories or clinics are contacted by telephone or tel-
efax in order to complete data.
Case definition
Case definition includes any person who had a direct or 
indirect proof of malaria parasite from their blood and 
whose country of residence was Germany at the time of 
diagnosis.
Data analysis
STATA SE14 and Microsoft Excel 2010 was used for 
performing time series analysis on notification data. 
Since 2001, when the German Infection Protection Act 
came into force, data was collected in a consistent man-
ner, therefore data from 2001 to 2016 was included. The 
‘year of notification’ was set as time variable. In order to 
be able to distinguish sub-groups among malaria cases 
according to their travel history and country of infection, 
four groups of different origin were defined:
Group 1:  ‘native German cases’ were cases with country 
of origin indicated as Germany.
Group 2:  ‘residents with migration background’ were 
cases whose country of origin was reported 
to be any other country than Germany and 
who were, not categorized as ‘recent refugees’ 
(group 3).
Group 3:  ‘recent refugees’ were cases fulfilling the fol-
lowing criteria:
  • Person reported as being in Germany as ‘immigrant/
asylum seeker/refugee’ or whose purpose of travel 
was indicated as ‘immigrant/asylum seeker/refugee’ 
or with no information of why being in Germany or 
purpose of travel AND who had arrived in Germany 
during 1 year prior to malaria diagnosis, OR.
  • In case of missing information on why being in Ger-
many and purpose of travel and/or date of arrival 
in Germany, person whose country of origin was a 
country which was among the top 10 countries of the 
refugee statistics of the German Federal Office for 
Migration and Refugees (BAMF) for the respective 
year of malaria notification. As the date of arrival was 
often incomplete with missing month and day, only 
the year of arrival was used for calculating the 1-year 
time interval.
Group 4:  cases not belonging to group 1–3, with incom-
plete or missing data concerning the criteria 
for group 1–3.
In order to calculate the percentage of cases who 
reported the use of chemoprophylaxis only cases with 
reported countries of infection, for which chemoprophy-
laxis was recommended for at least part of the country, 
based on the current malaria prophylaxis recommen-
dations of the German society of tropical medicine 
and international health [10], were taken into account. 
Travel destinations for which in the past, but not any 
more in 2016, malaria prophylaxis was recommended 
were excluded from the calculations. The denominator 
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included only cases with information on chemoprophy-
laxis use. Native German cases and cases with migration 
background were analysed separately. Recent refugees 
who acquired malaria in their home countries or on their 
travel route were not taken into account when looking at 
use of chemoprophylaxis.
If ‘mixed infection’ was indicated for Plasmodium spe-
cies, the data collection form did not indicate the differ-
ent species involved. Therefore, mixed infections were 
treated as ‘information on species missing’ and excluded 
when looking at the percentage of species and hospital 
admission rates according to different species.
Chi squared-test, t-test and Wilcoxon–Mann–Whit-
ney-test were used in order to compare sub-groups. 
Differences were considered statistically significant at 
p  <  0.05. Malaria incidence in refugees was calculated 
using data from BAMF [11] and malaria incidence in 
travellers for 2012–2016 using data on air travel depar-
tures to malaria-endemic countries, from  the  German 
Federal Statistical Office as denominators [12]. Recent 
refugees were excluded when calculating incidences of 
malaria based on air travel departure data.
Results
Data completeness
Overall, 11,678 malaria cases were included in the analy-
sis, which were notified in Germany over 16 years (2001–
2016). 618 cases not fulfilling the reference definition 
and 804 datasets, which were double notifications, were 
excluded from the analysis. Since 2001, reported malaria 
case numbers steadily declined from 1049 cases in 2001 
to 542 in 2007. Subsequently they remained relatively sta-
ble until 2013, and rose in 2014–2016 by 43% compared 
to the mean of the previous 10 years. The lowest annual 
number of malaria cases was reported in 2009 (n = 526) 
and the highest in 2015 (n = 1063).
Gender and age distribution and geographic origin 
of cases
During all years more male than female cases were 
observed. Between 2001 and 2013 male cases accounted 
for about two-thirds of cases (69.2%; 5878/8492). In 
2014–2016, the male proportion rose to more than three-
quarters of cases (75.7%; 2277/3008).
Native German cases were the largest group in 2001 
(45.5%; 477/1049) (Fig.  1). The absolute number was 
declining until 2009 (26.6%; 140/526), and was then 
showing a rising trend (24.1%; 231/960) until 2016. From 
2005, cases with migration background were the pre-
dominant group of malaria patients (except 2014 and 
2015) with 316 annual cases in 2016 (32.9%; 316/960) 
and an overall rising trend since 2005 (42.6%; 269/632). 
From 2001 to 2013 on average 10.2 (1.5%; 10.2/665.2) 
cases/year were notified among newly arriving refugees. 
In 2014 and 2015 refugees accounted for a mean percent-
age of 28.3 (292.5/1035.5), declining to 15.5% (150/960) 
in 2016.
The percentage of children and adolescents (< 18 years) 
among all malaria cases notified in Germany was fairly 
stable during 2001–2013 with a mean of 9.7% (in aver-
age 64.3/665.2 cases/year were <  18  years old) and rose 
to 16.9% in 2014–16 (mean: 171/1010.3 cases/year). This 
increase was almost entirely due to the group of recent 
refugees, who were significantly younger than other cases 
(p < 0.001).
Plasmodium species
During the entire observation period, P. falciparum was 
the most frequently reported species (Fig.  2), ranging 
from 57.2% (536/937) in 2014 to 85.8% (509/593) in 2010. 
Plasmodium vivax was the second most reported spe-
cies during 2001–2013: between 7.6% (45/593) in 2010 
and 18.1% (142/785) in 2002. In 2014 and 2015, num-
bers of vivax malaria rose to 31.3% (293/937) and 30.4% 
(305/1002), respectively, and came back down to 18.5% 
(168/907) in 2016. In 2014 and 2015, 22.3% (384/1724) 
of all P. vivax cases were refugees from Eritrea and 3.3% 
(20/598) from other countries in the Horn of Africa. 
In 2015 and 2016, 19.5% (92/473) were refugees from 
Afghanistan and Pakistan. When plotting species distri-
bution against time after withdrawing recent refugees 
and cases with missing information on their origin, the 
rise of P. vivax cases in 2014 and 2015 was no longer visi-
ble (Fig. 3b). While the percentage of P. falciparum infec-
tions declined and P. vivax infections increased in 2014 
and 2015, the absolute number of P. falciparum infec-
tions rose from 430 average annual cases in 2006–2012, 
to 516 in 2013–2014, and to 633 in 2015–2016 (Fig. 3a). 
Fig. 1 Malaria in Germany: frequency of case origin. Time series 
2001–2016 (n = 11,678)
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The percentage of tertian malaria cases without dif-
ferentiation was around 1.3% during 2001–2013 and 
rose to 4.2% in 2014/15. The percentage of Plasmo-
dium malariae, Plasmodium ovale and mixed malaria 
cases remained fairly stable over 16 years at around 2.5 
(292/11.678), 2.8 (331/11.678) and 3.2% (374/11.678), 
respectively. In absolute numbers, all types of malaria, 
except knowlesi malaria, showed an increase in 2014 
and 2015.
Over the whole observation period, 6 P. knowlesi cases 
were notified between 2012 and 2015. Five of those were 
native German persons who acquired malaria in Thai-
land: four were tourists and one visited friends and rela-
tives (VFR). For one knowlesi malaria case, neither travel 
destination nor reasons for travel were indicated.
While for Africa as region of infection P. falciparum 
dominated other types by far (80.1%; 6192/7734), P. vivax 
was the most frequently reported species from Asia 
(64.1%; 430/671), South and Central America (55.6%; 
114/205), and Oceania (68.4%; 65/95). From 2001 to 
2013, before the marked increase in P. vivax notifications, 
the majority of vivax malaria cases were of German origin 
(55.0%; 527/958) or had migration background (21.5%; 
206/958,), and 51/958 (5.3%) were recent refugees. Main 
countries of infection, accounting for more than half of 
the P. vivax cases, were India, Indonesia, Pakistan, Papua 
New Guinea, Brazil, and Cameroon.
In 2014–2016, 520 of 766 vivax malaria cases (67.9%) 
were recent refugees. 463 out of the 520 cases (89.0%) 
were men, 187 (36.1%) were children and adolescents 
under 18 years old; 415 (79.8%) were under 25 years old. 
The majority of those vivax cases originated from Afri-
can countries (79.2%; 412/520), particularly from Eritrea 
(n  =  378), Ethiopia (n  =  12) and East Africa without 
specification (n = 7).
Mean malaria incidence in Eritrean refugees in Ger-
many rose from 0.1% (yearly mean: 1/959.9) in 2001–
2013 to 1.4% (yearly mean: 225/1684) in 2014–2015. 
Besides vivax malaria cases, 19 tertian malaria cases 
without differentiation, 11 P. falciparum, and 6 P. ovale 
infections were notified among Eritrean refugees dur-
ing the observation period; 89.8% of all Eritrean refugees 
were male (442/492). Among refugees 21.2% of vivax 
malaria cases (71/335) originated from Asia in 2001–
2016, particularly from Afghanistan (n =  32) and Paki-
stan (n = 36).
Regions and countries in which infection was acquired
Malaria was acquired on the African continent by 7734 
out of 8710 (88.8%) cases, with indication of country/
region of infection (Fig.  4); 95.4% (3803/3987) of cases 
Fig. 2 Malaria in Germany: relative frequency of malaria species. Time 
series 2001–2016 (n = 10,794)
Fig. 3 Malaria in Germany. a Frequency of malaria species overall (n = 11,168). b Frequency of malaria species after withdrawal of refugees and 
cases with unknown origin (n = 7827). Time series 2001–2016
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with migration background and 82.6% (2983/3611) of 
native German cases had acquired malaria in Africa.
Overall, 54.7% (4718 of 8617 cases with indica-
tion of region) of cases had acquired malaria in West 
Africa. Infections from the Horn of Africa amounted to 
around 0.8% (54/6614) from 2001–2013, rose to 15.6% 
(210/1349) in 2014–2015 and dropped to 4.0% (26/654) 
in 2016 [2014–2016: 84.3% Eritrea (199/236), 12.7% 
(30/236) Ethiopia, 3.0% (7/236) Somalia]. In addition, in 
2014–2016, 98 cases from East Africa without further 
specification and 28 cases from Sudan as region or coun-
try of infection were notified.
Overall, the five most frequently mentioned countries 
of infection were African countries (number of cases 
with information on country of infection: n  =  8710): 
Ghana (17.2%; 1500/8710), Nigeria (14.5%; 1265/8710), 
Cameroon (9.7%; 849/8710), Kenya (5.6%; 487/8710), and 
Togo (5.1%; 448/8710). While Ghana and Kenya showed 
declining trends over 2001–2016, Togo was doubling 
case numbers in 2007–2016 compared to 2001–2006 
(Fig. 5). Eritrea, which played almost no role as a country 
of infection until 2013, showed a 30-fold increase from 
2013 to 2014/2015 with 97 and 85 cases, respectively 
(Fig. 5).
Out of 8710 cases with information on place of infec-
tion, 7.7% (n = 671/8710) acquired malaria in Asia. Some 
102 cases had acquired malaria in Asia in 2001, while 
the annual average of cases was 37.9 (range 17–64) in 
subsequent years. The percentage of cases acquiring 
malaria in Asia was relatively stable for most of the time, 
amounting to an average of 7.4% (559/7551), except for 
a peak of 16.1% (62/386) in 2012, and a small increase 
in 2015 (Fig.  4). The rise in 2012 was mainly due to an 
increase of acquired infections in Pakistan (n = 33) and 
India (n =  18), and in 2015/2016 due to an increase in 
cases from Afghanistan (mean n  =  18) and Pakistan 
(mean n =  17). While from 2001 to 2005 the majority 
of cases from Asia had acquired malaria in Southeast 
Asia [between 48.6% (17/35) in 2005 and 75.5% (77/102) 
in 2001, notably in Indonesia and Thailand], from 2010 
onwards South Asia was the most important region of 
infection (Afghanistan, Pakistan, India) representing 
between 62.5% (10/16) in 2013 and 98.0% (50/51) in 2016 
of infections from the Asian continent.
Two-hundred and five (2.4%; 205/8710) cases had 
acquired malaria in South and Central America and 1.1% 
(95/8710) in Oceania. Infections from those destinations 
showed an overall declining trend (Fig. 4). The most fre-
quently reported countries of infection in Oceania and 
South and Central America were Papua New Guinea 
(n = 86), Brazil (n = 64), Dominican Republic (n = 34), 
and Venezuela (n =  23). An average of 13 annual cases 
were reported for Papua New Guinea in 2001–2004, 
which came down to 1–2 cases/year in 2009–2016.
Cases with countries of infection in Europe were 
making up 0.06% (5/8710) of all cases with informa-
tion on place of infection. Two cases had falciparum 
malaria, 2 vivax malaria and 1 had a mixed infection. 
Two cases were reported with acquisition of malaria in 
France (without further specification, likely acquired in 
French overseas departments) and 3 in Germany. Noso-
comial transmission was the probable cause for 2 cases 
with acquisition in Germany in 2007 and 2016. Both 
cases were women in their 30s, who were hospitalized 
at the same hospital ward as a patient with imported 
malaria caused by P. falciparum. Intense epidemiologi-
cal investigations could not clarify the circumstances of 
Fig. 4 Malaria in Germany: relative frequency of continents of infec‑
tion. Time series 2001–2016 (n = 8710)
Fig. 5 Malaria in Germany: relative frequency of malaria imported 
from Ghana, Eritrea, Kenya, and Togo. Time series 2001–2016 
(n = 8710)
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transmission. For the remaining case information on the 
suspected mode of transmission was not provided.
Use of chemoprophylaxis and reasons for travel
For calculation of the percentage of cases who had report-
edly taken chemoprophylaxis only cases with reported 
countries or regions of infection, for which chemopro-
phylaxis was recommended were taken into account. 
Overall 1695 (24.3%) cases out of 6984 for whom this 
information was available had reportedly taken any type 
of chemoprophylaxis. For 2896 out of 9880 (29.3%) cases, 
information on chemoprophylaxis use was missing.
Native German cases were significantly more likely to 
have taken chemoprophylaxis than cases with migra-
tion background [32.6% (943/2892) vs. 17.9% (669/3747); 
p < 0.001]. The percentage of cases taking chemoprophy-
laxis declined over the observation period in both groups 
(Fig.  6). Women were significantly more likely to have 
taken chemoprophylaxis than men [27.9% (589/2109) 
vs. 22.5% (1084/4809); p  <  0.001]. Cases <  30  years of 
age among the native German sub group had signifi-
cantly more frequently taken prophylaxis than cases aged 
30 and older [41.7% (423/1014) vs. 27.7% (520/1878); 
p < 0.001]. This was not the case in the group of migrants 
(cases <  30  years of age: 16.1%, 160/997 vs. cases aged 
30 and older: 18.5%, 509/2750; p =  0.082). Chemopro-
phylaxis did not differ significantly between persons 
who travelled as tourists compared to those travelling 
for work, education, and training [28.8% (358/1243) vs. 
31.7% (374/1181); p =  0.124]. Cases who went for VFR 
were less likely to have taken chemoprophylaxis than oth-
ers [22.4% (866/3867) vs. 30.2% (732/2424), p < 0.001].
By far the foremost reason for travelling to a 
malaria-endemic country among cases with migration 
background was VFR. For native German cases, the fore-
most reason for travel was tourism, in the years 2001–
2007. From 2008, work, education and training and VFR 
became equally important (Fig.  7). Malaria incidence 
among air travellers to malaria-endemic countries has 
increased continuously from 0.52/1000 travellers in 2012 
to 0.72/1000 travellers in 2016.
Hospital admissions and fatalities
The overall hospital admission rate was fairly sta-
ble over the observation period (annual mean: 65.1%; 
7601/11,678) and equal among the different groups. Chil-
dren and patients with falciparum malaria or knowlesi 
malaria were significantly more frequently hospitalized 
than adults and patients with other types of malaria 
(p  =  0.002 and p  <  0.001, respectively). Hospitaliza-
tion was reported for 68.7% (5641/8217) of falciparum 
malaria, 59.3% (1352/2279) of tertian malaria, 47.3% 
(138/292) of quartan  malaria cases and for 5 out of 6 
knowlesi cases. The mean lag time between symptom 
onset and start of treatment was slightly longer in cases 
with migration background and refugees (6.1 days) than 
in native German cases (5.6 days; p = 0.121).
During the observation period, 51 deaths due to 
malaria were notified, making up a yearly mean of 3.2 
deaths (0.4%, 51/11,678; range 1–8). The largest num-
ber of fatal cases occurred in the year 2001. Plasmodium 
falciparum was causative for 43/51 (84.3%) of those 
fatalities, 4 were due to mixed infections. In 4 fatalities, 
Plasmodium species was not specified. Forty-two fatal 
cases were of German origin (82.4%; 42/51), 7 were resi-
dents with migration background (13.7%, 7/51), 1 was a 
recent refugee, and for 1 no information about the ori-
gin was indicated. Among the fatal cases, infection was 
Fig. 6 Malaria in Germany: chemoprophylaxis use in native German 
cases (n = 2896) vs. cases with migration background (n = 3750). 
Time series 2001–2016
Fig. 7 Malaria in Germany: reasons for travel among native German 
cases (n = 3761) vs. cases with migration background (n = 4357). 
Time series 2001–2016 (Multiple answers possible.)
Page 7 of 10Vygen‑Bonnet and Stark  Malar J  (2018) 17:28 
most frequently acquired in Africa (88.2%; 45/51). Most 
frequently reported probable countries of infection were: 
Kenya (8/51), Ghana (6/51), Cameroon (5/51), Gam-
bia (4/51) and Uganda, Togo and Senegal (3/51 each). 
Seven of the fatal cases, 6 native German cases and 1 
person with migration background, had reportedly taken 
chemoprophylaxis. Three had taken mefloquine, one a 
atovaquone and proguanil combination medication, for 
three information on the regimen was unavailable. The 
delay between symptom onset and start of treatment 
could be calculated for 7645 non fatal cases and 24 fatali-
ties. The mean was in both groups 5.8 days with an inter-
quartile rage of 0–213 and 2–8  days, respectively. For 
treatment 28/51 (38.9%) fatal cases had received quinine, 
17/51 (23.6%) doxycycline, 4/51 (5.6%) artesunate, 3/51 
(4.2%) artemether, and 2/51 (2.8%) each atovaquone and 
mefloquine. Twenty (39.2%; 20/51) had received more 
than one drug and for 16/51 cases the information on the 
administered treatment was missing.
Discussion
Time series analysis provides valuable data on trends 
of imported malaria cases in Germany. The decreasing 
trend in 2001–2009 did not continue. On the contrary, 
a sharp increase in malaria notifications was observed 
in 2014–2016 due to a high number of refugees from 
malaria-endemic countries arriving in Germany. At the 
same time, a mild increasing trend of malaria notifica-
tions over the past 10  years was observed among the 
German (non-refugee) population, along with changes in 
travel reasons and destinations and a decline in chemo-
prophylaxis use.
The largest part of the rise in P. vivax notifications 
was due to young male Eritrean refugees, as has been 
reported in 2014 from Sweden [8] and in 2016 from a 
German tropical medicine hospital [6]. Gender distribu-
tion in the German surveillance data showed a predomi-
nance of male cases for all malaria notifications during all 
years (men:women 2:1). This was attributed to differences 
in travel and prevention behaviour and to the composi-
tion of groups of people migrating to Germany [7]. The 
gender difference in 2014–2016 was more pronounced 
(men:women 3:1) and cases were on average significantly 
younger than in previous years. Why was there such 
a sudden increase of young men fleeing from Eritrea in 
2014? According to the UN Human Rights Council [13] 
and Amnesty International [14] the main driver to leave 
Eritrea was the national conscription practice into mili-
tary services which in practice amounts to forced labour 
[13, 14]. Since the law of the national service came into 
force in 1995, Eritreans have been fleeing their country, 
with large numbers residing in Sudan and Ethiopia [15]. 
According to the United Nations High Commissioner for 
Refugees (UNHCR) an intensified recruitment drive in 
2014 and increasingly bad living conditions in the camps 
in neighbouring countries were causing a nearly 3-fold 
increase of Eritrean refugees in Europe in 2014, mainly in 
Germany, Sweden, Switzerland and the Netherlands [15]. 
The German Federal Office of Migration and Refugees 
reported a more than 23-fold increase of newly arriving 
Eritreans in 2014 and 2015, compared to the years 2001–
2012 [11]. However, Eritreans accounted for 2.5% of asy-
lum applications registered in 2015 in Germany only [11].
Most of the Eritrean cases presented with vivax 
malaria, only 5% were notified with falciparum malaria. 
According to the World Malaria Report 2016 [1], the pre-
dominant Plasmodium species in Eritrea and along the 
travel route (Ethiopia and Sudan) is P. falciparum (Eri-
trea: 75%; P. vivax: 25% [1]). As most Eritrean refugees 
travelled overland via Ethiopia and Sudan to Libya and 
then by boat to Italy [15], their travel time to arrival in 
Germany is longer than the usual incubation period for 
falciparum malaria. Sonden et  al. (pers. comm.) report 
that a considerable number of cases arriving in Germany 
and Sweden had sought malaria treatment during migra-
tion, notably in Italy where national health services and 
non-governmental organizations provide medical care 
[16]. The high incidence of P. vivax hints at an accumula-
tion of cases due to an increased probability of malaria 
acquisition in people who may have spent the nights out-
side during several months of travel, inadequately taken 
medication for relapse prevention (i.e., primaquine), due 
to unavailability or poor compliance, in addition to ongo-
ing increased P. vivax transmission or outbreaks along 
the migration route (Sonden et al. pers. comm.).
Alongside refugees from Eritrea, there was an increase 
of malaria infections in refugees arriving from other 
countries of the Horn of Africa, Sudan, Pakistan, and 
Afghanistan. When plotting species distribution against 
time after withdrawing the population of recent refugees 
and cases without information on their origin, the rise 
of P. vivax cases in 2014 and 2015 was no longer visible 
(Fig. 3b). The refugee population, comprising many teen-
agers and young adults, might be more vulnerable and 
potentially less self-competent in attending medical care 
than adults who are acquainted with the German health 
care system. Clinicians must be aware of the possibility 
of malaria infection in refugees from the aforementioned 
countries, even if their arrival to Germany dates back 
several months. Relapses may occur frequently in inad-
equately treated patients and can occur when patients 
have resided in Germany for some time. Timely diagno-
sis is especially important, particularly as severe clinical 
pictures in this population were reported from different 
European countries probably due to delayed diagnosis 
and a generally impaired health status, presumably partly 
Page 8 of 10Vygen‑Bonnet and Stark  Malar J  (2018) 17:28 
caused by the long and strenuous migration (Sonden 
et  al. pers. comm.). This is an interesting observation, 
given that people from malaria endemic countries are 
likely to have acquired semi-immunity and should thus 
be partly protected against severe disease. The surveil-
lance data do not provide any clinical information that 
could help to better understand this contradiction.
Overall, from 2001 to 2016, by far the most malaria 
infections were acquired in Africa with little variation in 
the most frequently reported countries (Ghana, Nigeria, 
Cameroon). The percentage of Asian countries of infec-
tion was low. It was fairly stable over the 15-year period 
(around 7%) with the exception of a 10% increase in 
2012, which was mainly due to cases recently immigrated 
to Germany from Pakistan [17], and a rise in 2015 due 
to cases from Afghanistan and Pakistan. At the same 
time, groups who acquired malaria in Asia and coun-
tries of infection within Asia have changed. During the 
first half of the observation period the majority of cases 
were native Germans who had travelled as tourists to 
Southeast Asia, mainly to Indonesia and Thailand. From 
2009 onwards, most cases were refugees or had migra-
tion background and were reported to have acquired 
malaria in Pakistan, India and Afghanistan. Southeast 
Asian countries were four times more frequently named 
as country of infection between 2001 and 2008 than 
between 2009 and 2016. This change may reflect an alter-
ing pattern of malaria epidemiology in Southeast Asia, 
or changes of travel destinations, or both. The risk for 
malaria in most regions in Southeast Asia is categorized 
as low, very low or non-existent. No regular chemopro-
phylaxis is recommended and carrying of standby emer-
gency treatment for only some destinations [10]. The risk 
is still considered high for some regions in Indonesia [10]. 
But a decrease of malaria incidence in European travellers 
to Indonesia over the past decade, as described by Johans-
son Århem et  al. [18], was also reflected in surveillance 
data for Indonesia and neighbouring Papua New Guinea.
Five knowlesi malaria infections acquired in Thailand 
were reported, and one additional without indication of 
travel destination. All those cases were reported between 
2012 and 2016, mainly in tourists. It is likely that other 
P. knowlesi infections might have been misclassified as 
other malaria species, as correct microscopy diagnosis 
is complicated due to morphological similarity of the 
parasite with P. falciparum and P. malariae [19]. In addi-
tion, the same drugs as used for other types of malaria 
are effective in P. knowlesi cases [19]. It remains to be 
seen whether there will be more reports of P. knowlesi 
infections in the future as awareness of this Plasmodium 
species among microbiologists and clinicians rises and 
diagnostic tests improve.
An overall moderately rising trend of malaria notifica-
tions over the past 10  years was present among native 
German cases and residents with migration background. 
According to the German Federal Statistical Office, the 
number of air travel departures to malaria-endemic 
countries has increased by 10% between 2012 and 2016 
[12]. Since 2006, the number of cases with migration 
background has exceeded native German cases. VFR 
was the foremost reported travel reason for cases with 
migration background during all 16 years of malaria sur-
veillance. The largest sub-group of malaria cases overall 
were adult male residents with migration background 
who acquired falciparum malaria in Africa when VFR, 
sub-Sahara Africa and in particular West Africa being 
the regions with the highest risk of malaria acquisition. 
Among native German cases the picture has changed 
over the years. Tourism used to be the most important 
motive for travel, but its predominance was becoming 
less and less pronounced, while VFR, and work, educa-
tion and training were becoming equally important rea-
sons for travel. In the context of globalization, an overall 
growing mobility and an increasing number of people 
who are working and living abroad, and thus receiving 
friends and relatives for visits, might partly explain the 
overall increase of cases.
This data, showing an increasing trend of imported 
malaria in Germany, underlines the importance of pre-
travel counselling, as malaria in travellers is at a large 
part preventable [20]. Schlagenhauf et  al. [20] postulate 
that pre-travel consultations are associated with reduced 
morbidity of falciparum malaria in all traveller sub-
groups. German surveillance data and notably data on 
countries or regions of infection are used for updating 
the malaria prophylaxis recommendations of the German 
society of tropical medicine and international health.
Inherently, malaria cases show a low percentage of 
chemoprophylaxis use, as compliant prophylaxis users 
are less likely to develop malaria. Nevertheless the 
reported share of chemoprophylaxis use was low (24%) 
compared to reports from other European countries [21, 
22] and the USA [23], where it ranged from 28 to 40%. 
When calculating this percentage only cases with “yes” or 
“no” for chemoprophylaxis use were taken into account 
and not cases lacking information on this topic. There-
fore, the percentage of chemoprophylaxis users was 
probably overestimated, as one can assume that cases 
with no information are more likely to have not taken 
chemoprophylaxis. Furthermore, the overall share of 
cases who did take chemoprophylaxis was continuously 
decreasing over the observation period. A similar trend is 
observed in other European countries [24] and the USA 
[23, 24]. The observed decrease was most pronounced 
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among native German cases. Reasons can only be spec-
ulated about. Growing mobility and perceived easiness 
and affordability of travel to exotic destinations may alter 
a person’s attitude towards travel preparations and risk 
perception. Fear of side effects may also be a reason not 
to take chemoprophylaxis. An increasing trend of malaria 
incidence among air travellers to countries with known 
malaria transmission was observed between 2012 and 
2016. Single incidence calculations might be quite inac-
curate as neither overland (non-air) travel nor the varying 
malaria endemicity in different countries, nor seasonality 
were taken into account, but the overall trend is worrying 
[12].
The proportion of cases who took chemoprophy-
laxis was markedly lower among cases with migration 
background than among native German cases. This dis-
parity is known [22, 24–26] and is mostly attributed to 
a lower risk perception of acquiring malaria and of suf-
fering from severe malaria, and the lower uptake of 
pre-travel counselling by the population with migration 
background [25, 26]. This is particularly worrying since 
people whose families originate from malaria-endemic 
countries tend to use less mosquito protection measures, 
travel for longer periods and often to more remote areas 
than tourists and business travellers. In addition, this 
group of people is reported to seek medical attention in 
case of a febrile illness later upon return to Europe [25, 
26]. Interestingly, despite residents with migration back-
ground taking less chemoprophylaxis, there were fewer 
fatal cases among them than among native German 
cases. This might be due to persisting partial immunity 
among cases originating from malaria-endemic coun-
tries. The surveillance data does not give information on 
attendance of pre-travel consultations. Awareness of the 
risk of malaria infection among travellers needs enhance-
ment. Strategies aiming to increase uptake of and com-
pliance to malaria chemoprophylaxis recommendations 
are needed, especially targeting those groups who were 
identified as taking only rarely chemoprophylaxis, e.g. 
residents with migration background. The present data 
reveal that malaria cases frequently report travel to high-
risk areas, such as West Africa and therefore provide 
important travel medicine information for the training of 
physicians.
Notification data suffers from under-reporting. As a 
large number of cases was primarily diagnosed or trans-
ferred to large specialized centres for tropical medicine, 
which have well established notification mechanisms, 
a selection bias is unlikely to occur. Education of physi-
cians to completely fill in the notification forms (e.g. 
country of infection) is needed to improve complete-
ness of data. Misclassification of cases to different patient 
groups is possible. Recent refugees and residents with 
migration background might have less complete notifi-
cation forms due to communication barriers. Therefore, 
more cases from those two groups might have been clas-
sified into the group with unknown origin than native 
German cases. This might have led to underestimation of 
a number of results, such as the problem of vivax malaria 
in refugee cases and the predominance of cases with 
migration background among all malaria cases. The noti-
fication form asks for the probable country of infection 
and does not include questions on exact travel destina-
tions within the countries. When calculating percentages 
of chemoprophylaxis use all cases, who had travelled to 
countries with recommendation for chemoprophylaxis 
for at least part of the country were included. This might 
have led to an underestimation of chemoprophylaxis use. 
Changes over time in recommendations for prophylaxis 
could not be taken into account. Travel destinations for 
which in the past malaria prophylaxis was recommended, 
e.g. some countries in Southeast Asia, were thus excluded 
from the calculations. There is no reason to assume that 
those cases were systematically different from others.
Conclusions
The steep rise in vivax malaria notifications in 2014 and 
2015 was mainly due to newly arriving refugees from 
Eritrea but also due to refugees from other countries 
of the Horn of Africa and South Asia, predominantly 
young men. Clinicians should include malaria in their 
differential diagnosis in case of a febrile illness in this 
population even if arrival to Germany dates back several 
months.
Over the past 10  years malaria notifications among 
native Germans and residents with migration background 
showed an increasing trend. Use of chemoprophylaxis 
was insufficient in both groups and deteriorating. New 
strategies need to be found in order to increase compli-
ance to chemoprophylaxis recommendations. The sur-
veillance provides valuable data for the epidemiological 
assessment of imported malaria in Germany.
Authors’ contributions
SVB conducted the data analysis, interpreted the results and wrote the manu‑
script; KS gave scientific support and revised the manuscript. Both authors 




The authors declare that they have no competing interests.
Availability of data and materials
The largest part of the dataset analysed during the current study is publicly 
available on the Robert Koch‑Institute’s website: a dataset with additional vari‑
ables is available from the corresponding author on reasonable request.
Consent for publication
Not applicable.
Page 10 of 10Vygen‑Bonnet and Stark  Malar J  (2018) 17:28 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ethics approval and consent to participate
Not applicable.
Funding
The work presented in this manuscript has exclusively been funded by the 
institutional funds of the authors.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 26 October 2017   Accepted: 8 January 2018
References
 1. WHO. World Malaria Report 2016. Geneva, World Health Organiza‑
tion. 2016. http://www.who.int/malaria/publications/world‑malaria‑
report‑2016/en/. Accessed 4 Jan 2018.
 2. WHO. From over 90, 000 cases to zero in two decades: the European 
Region is malaria free. Geneva, World Health Organization. 2018. http://
www.euro.who.int/en/media‑centre/sections/press‑releases/2016/04/
from‑over‑90‑000‑cases‑to‑zero‑in‑two‑decades‑the‑european‑region‑is‑
malaria‑free. Accessed 4 Jan 2018.
 3. Zoller T, Naucke TJ, May J, Hoffmeister B, Flick H, Williams CJ, et al. Malaria 
transmission in non‑endemic areas: case report, review of the literature 
and implications for public health management. Malar J. 2009;8:71.
 4. Kruger A, Rech A, Su XZ, Tannich E. Two cases of autochthonous Plasmo-
dium falciparum malaria in Germany with evidence for local transmission 
by indigenous Anopheles plumbeus. Trop Med Int Health. 2001;6:983–5.
 5. Infection Protection Act (IfSG). 2000. http://www.sozialgesetzbuch‑sgb.
de/ifsg/6.html. Accessed 4 Jan 2018.
 6. Roggelin L, Tappe D, Noack B, Addo MM, Tannich E, Rothe C. Sharp 
increase of imported Plasmodium vivax malaria seen in migrants from 
Eritrea in Hamburg, Germany. Malar J. 2016;15:325.
 7. Robert Koch‑Institute. Infektionsepidemiologisches Jahrbuch meldepfli‑
chtiger Krankheiten für 2016 (Yearbook of infectious diseases in Germany, 
2016) Berlin. 2017. https://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahr‑
buch_2016.pdf?__blob=publicationFile. Accessed 4 Jan 2018.
 8. Sonden K, Castro E, Tornnberg L, Stenstrom C, Tegnell A, Farnert A. High 
incidence of Plasmodium vivax malaria in newly arrived Eritrean refugees 
in Sweden since May 2014. Euro Surveill. 2014;19:pii 20890. http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=20890.
 9. Gier B, Suryapranata FS, Croughs M, Genderen PJ, Keuter M, Visser LG, 
et al. Increase in imported malaria in the Netherlands in asylum seekers 
and VFR travellers. Malar J. 2017;16:60.
 10. Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit 
(DTG) e. V. Empfehlungen zur Malariavorbeugung. 2017. https://www.dtg.
org/images/Empfehlungen/DTG_Malaria_2017.pdf. Accessed 4 Jan 2018.
 11. Federal Office for Migration and Refugees (Bundesamt für Migration 
und Flüchtlinge). Migrationsbericht des Bundesamtes für Migration und 
Flüchtlinge im Auftrag der Bundesregierung. Migrationsbericht. 2015. 
https://www.bamf.de/SharedDocs/Anlagen/DE/Publikationen/Migra‑
tionsberichte/migrationsbericht‑2015.html;jsessionid=C25233AB573151
C773AFC408C7B0FDAB.2_cid286?nn=1362958. Accessed 4 Jan 2018.




elid=1508419675311&index=12017. Accessed 4 Jan 2018.
 13. Office of the United Nations High Commissioner for Human Rights 
(OHCHR) Human Rights Council. Detailed findings of the commission of 
inquiry on human rights in Eritrea. 2016. http://www.ohchr.org/Docu‑
ments/HRBodies/HRCouncil/CoIEritrea/A_HRC_32_CRP.1_read‑only.pdf. 
Accessed 20 July 2017.
 14. Amnesty International. Eritrea: Just deserters: Why indefinite National Ser‑
vice in Eritrea has created a generation of refugees (December 2015 edi‑
tion). 2015. https://www.amnesty.org/en/documents/afr64/2930/2015/
en/. Accessed 20 July 2017.
 15. United Nations High Commissionar for Refugees (UNHCR). Sharp 
increase in number of Eritrean refugees and asylum‑seekers in 
Europe, Ethiopia and Sudan. 2014. http://www.unhcr.org/news/
briefing/2014/11/5465fea1381/sharp‑increase‑number‑eritrean‑refu‑
gees‑asylum‑seekers‑europe‑ethiopia.html. Accessed 4 Jan 2018.
 16. Doctors without borders. Out of sight. Asylum seekers and refugees in 
Italy: informal settlements and social marginalization. 2016. https://www.
aerzte‑ohne‑grenzen.de/sites/germany/files/attachments/aerzte_ohne_
grenzen_out_of_sight_report.pdf. Accessed 28 Aug 2017.
 17. Stark K, Schoneberg I. Increase in malaria cases imported from Pakistan to 
Germany in 2012. Euro Surveill. 2012;17:pii 20320.
 18. Johansson Arhem KM, Gysin N, Nielsen HV, Surya A, Hellgren U. Low and 
declining risk for malaria in visitors to Indonesia: a review of local Indone‑
sian and European travelers’ data and a suggestion for new prophylactic 
guidelines. J Travel Med. 2015;22:389–95.
 19. Müller M, Schlagenhauf P. Plasmodium knowlesi in travellers, update 2014. 
Int J Infect Dis. 2014;22:55–64.
 20. Schlagenhauf P, Weld L, Goorhuis A, Gautret P, Weber R, von Sonnenburg 
F, et al. Travel‑associated infection presenting in Europe (2008–12): an 
analysis of EuroTravNet longitudinal, surveillance data, and evaluation of 
the effect of the pre‑travel consultation. Lancet Infect Dis. 2015;15:55–64.
 21. Kuna A, Gajewski M, Stanczak J. Evaluation of knowledge and use of the 
malaria prevention measures among the patients of the Department of 
Tropical and Parasitic Diseases University Center of Maritime and Tropical 
Medicine, Gdynia, based on a questionnaire performed in the years 
2012–2013. Przegl Epidemiol. 2017;71:33–44.
 22. Jelinek T, Schulte C, Behrens R, Grobusch M, Coulaud J, Bisoffi Z, et al. 
Imported Falciparum malaria in Europe: sentinel surveillance data from 
the European network on surveillance of imported infectious diseases. 
Clin Infect Dis. 2002;34:572–6.
 23. Cullen KA, Mace KE, Arguin PM. Malaria Surveillance—United States, 
2013. MMWR Surveill Summ. 2016;65:1–22.
 24. Rees E, Saavedra‑Campos M, Usdin M, Anderson C, Freedman J, de Burgh 
J, et al. Trend analysis of imported malaria in London; observational study 
2000–2014. Travel Med Infect Dis. 2017;17:35–42.
 25. Ladhani S, Aibara RJ, Riordan FA, Shingadia D. Imported malaria in chil‑
dren: a review of clinical studies. Lancet Infect Dis. 2007;7:349–57.
 26. Sanchez BS, Tato LMP, Martin SG, Perez E, Grasa C, Valderrama S, et al. 
Imported malaria in children in Madrid, Spain, 2007–2013. Enferm Infecc 
Microbiol Clin. 2017;35:348–53.
